India Market Growth and Financial Performance
Lupin Today
Operating from a position of strength
Global Presence
Local Leadership
LUPIN
Geographically Diverse
(FY23 Sales)
13th
Largest Generic
Company
3rd
Largest in
the US
7th
India Pharma
Market Rank
37%
INDIA
8%
(by prescriptions³)
Developed
Markets
(by sales³)
(by sales¹)
$2 bn
4th
Largest
Australia
Largest
32%
US
7th
14%
South Africa
Gx
Gx
Emerging
7%
(by sales)
Developing
Adjacencies
(by sales5)
Markets
ΑΡΙ
Annual sales in FY23
$233 mn
EBITDA in FY23
20,500+
Lupinytts
Reaching lives in
100+ countries
1- Global ranking based on LTM Sep-23 sales
With Global Infrastructure
And Growing Sustainably
~13% reduction in Scope 1 and
2 emissions²
Adding 22MW
Renewable energy
capacity in FY24
13 IQVIA Qtr Dec-23
14 IQVIA MAT Dec-23
15 IQVIA MAT Dec-23
15
Manufacturing
R&D
7
Sites
Sites
Renewable energy
share of 5% in
FY23
across India, the US, Netherlands,
Brazil and Mexico
| 2 Reduction in FY23 from base of FY20
16View entire presentation